Get the Stockscreener App
8.24
0.00%
0.00
Harvard Bioscience Inc stock is traded at $8.24, with a volume of 8,924.
It is up +0.00% in the last 24 hours and up +2.62% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
See More
Previous Close:
$8.24
Open:
$8.415
24h Volume:
8,924
Relative Volume:
0.49
Market Cap:
$37.51M
Revenue:
$85.53M
Net Income/Loss:
$-9.78M
P/E Ratio:
-3.7536
EPS:
-2.1952
Net Cash Flow:
$1.28M
1W Performance:
-3.06%
1M Performance:
+2.62%
6M Performance:
+91.18%
1Y Performance:
+96.38%
1-Day Range:
$8.23
$8.53
1-Week Range:
$7.98
$8.80
52-Week Range:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, RMD, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
8.24 | 37.51M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience creates scientific advisory board - Investing.com
Harvard Bioscience forms scientific advisory board with four members - StreetInsider
Harvard Bioscience Announces Creation Of Scientific Advisory Board - TradingView
Harvard Bioscience Announces Creation of Scientific Advisory Board - GlobeNewswire
Harvard Bioscience, Inc. Announces Creation of Scientific Advisory Board - www.marketscreener.com
Harvard Bioscience stock gained 1.92 percent on October 5, 2026 - AD HOC NEWS
Harvard Bioscience grows revenue 11.10 percent: what it means for Harvard Bioscience stock - AD HOC NEWS
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Harvard Bioscience stock holds at USD 7.92 after reverse split - AD HOC NEWS
Over 5% stake disclosed in Harvard Bioscience (HBIO) - Stock Titan
Harvard Bioscience stock trades steady as investors look to latest revenue trends - ad-hoc-news.de
Harvard (HBIO) Chart: Records a 0.13% Increase to $7.49; Price Context: the Price Remains Bounded by the Supplied Support and Resistance on the DayVolatility Surface - vinanet.vn
Harvard Bioscience Insider Confidence Rewarded, Stock Hits US$32m Market Cap - Sahm
Harvard Bioscience Insider Confidence Rewarded, Stock Hits US$32m Market Cap - simplywall.st
Harvard (HBIO) Results Review: EPS Exceeds Its Estimate in the Current Update; Session Move: The Stock Gains 1.58% at the CloseNet Profit Margin - vinanet.vn
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript - AOL.ca
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com South Africa
HBIO Maintained by Benchmark -- Price Target Raised to $7.50 - GuruFocus
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com India
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com UK
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Harvard Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-08-12 - Seeking Alpha
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary - TradingView
Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs - Stock Titan
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus
HBIO Looks 66.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ... - Yahoo Finance
Harvard Bioscience Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com Nigeria
HBio Q2 2026 slides: revenue up 11%, China growth drives guidance raise - Investing.com Nigeria
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance - Yahoo Finance
Harvard Bioscience Raises Full-Year 2026 Revenue Guidance After Strong Second-Quarter Growth - Minichart
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com
Why is Harvard Bioscience stock gaining today? By Investing.com - Investing.com Canada
Is Harvard Bioscience Inc (HBIO) Undervalued After Q2 Earnings B - GuruFocus
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com South Africa
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com Australia
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com Canada
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience Announces Second Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q2 Earnings Snapshot - marketscreener.com
Harvard Bioscience: Q2 Earnings Snapshot - AOL.com
Harvard Bioscience: Q2 Earnings Snapshot - KTVB
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook - TradingView
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million - Quiver Quantitative
Harvard Bioscience Announces Second Quarter 2026 Financial Results - marketscreener.com
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harvard Bioscience Inc Stock (HBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
1.13%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):